John W. Jackson

The company had its first product, THALOMID, approved in July 1998 for erythema nodosum leprosum, a complication of leprosy and the company had its first profitable quarter in 2000.  In August 2001, Celgene received an approvable letter from the FDA for d-methylphenidate, the chirally pure version of Ritalin. 

Prior to joining Celgene, Mr. Jackson held senior positions with Merck and American Cyanamid.

He holds a BA from Yale University and an MBA from INSEAD in France.

Mr. Jackson is the Immediate Past Chair of the Biotechnology Council of New Jersey. In that position, he helped to move the important Tax Credit Transfer legislation forward.